BeyondSpring Inc
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
100 Campus Dr Ste 4 Side, Florham Park, ...Phone Number
(646) 305-6387Website
www.beyondspringpharma.comRevenue
<$5 MillionStock Symbol
BYSIIndustry
About BeyondSpring Inc
BeyondSpring Pharmaceuticals is a global biopharmaceutical company dedicated to developing innovative cancer therapies aimed at improving clinical outcomes for patients. The company focuses on treatments in both China and the United States, with its lead clinical asset, Plinabulin, being a first-in-class immune modulator designed to enhance anti-cancer efficacy and safety. BeyondSpring's mission is to raise the standard of care for cancer patients by providing transformative medicines that improve overall survival and quality of life. Their targeted pipeline addresses high-impact cancer indications, demonstrating a commitment to patient-first development and meaningful therapeutic advancements.Explore more
BeyondSpring Inc Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to BeyondSpring Inc
Compare insights from companies similar to BeyondSpring Inc, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
BeyondSpring Inc Tech Stack
A closer look at the technologies used by BeyondSpring Inc
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BeyondSpring Inc
Sign Up For FreeTo access detailed company insights
BeyondSpring Pharmaceuticals is a global biopharmaceutical company dedicated to developing innovative cancer therapies aimed at improving clinical outcomes for patients. The company focuses on treatments in both China and the United States, with its lead clinical asset, Plinabulin, being a first-in-class immune modulator designed to enhance anti-ca... Read More
